Transcend Therapeutics, a mental health-focused biotechnology company, raised USD 40 million in a Series A funding round led by Alpha Wave Global and Integrated Investment Partners. This brings the total funding raised by the company to USD 42 million.
The funds will be used to launch multiple clinical trials, including a Phase II study, using the firm’s proprietary psychoactive compound, which is claimed to be more accessible than outright psychedelic treatment.
US-based Transcend Therapeutics develops psychoactive drugs aiming to support patients with neuropsychiatric diseases. The company’s lead compound methylone (TSND-201) has demonstrated strong results in patients that suffer from PTSD.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.